|
|
 Previous Article | Table of Contents | Next Article 
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative
disorders
S O'Brien, R Kurzrock, M Duvic, H Kantarjian, S Stass, LE Robertson, E Estey, S Pierce and MJ Keating
Department of Hematology, University of Texas M.D. Anderson Cancer Center,
Houston 77030.
Mature T-cell lymphoproliferative disorders comprise a heterogenous group
of diseases for which there is no standard therapy. These disorders are
uncommon, and are usually treated similarly to their B- cell counterparts,
but with less success. Nucleoside analogues have proven effective in
indolent B-cell disorders but have been less well explored in T-cell
malignancies. We treated 22 patients with mature T- cell
lymphoproliferative diseases with 2-chlorodeoxyadenosine (2-CDA)
administered as a continuous infusion at a daily dose of 4 mg/m2 over 7
days. Nineteen of the patients had received prior therapy with a median
number of prior regimens of three. Eleven patients had leukemia or large
granular lymphocytosis, eight patients had mycosis fungoides, and three had
T-cell lymphoma. Nine patients (41%) responded to 2-CDA. Four of the
patients had responses that were complete remissions, and three of these
four patients remain in remission at 23, 24, and 23 months. The only
important toxic effects were fever or infection, seen during 38% of
courses. In conclusion, 2-CDA appears to be an effective therapy in T-cell
lymphoproliferative disorders and deserves wider evaluation in this subset
of patients.
Volume 84,
Issue 3,
pp. 733-738,
08/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Ravandi and S. O'Brien
Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
December 1, 2005;
80(12):
1660 - 1674.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, B. Cazin, S. Coutre, R. Birhiray, T. Kovacsovics, W. Langer, B. Leber, T. Maughan, K. Rai, G. Tjonnfjord, et al.
Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed
J. Clin. Oncol.,
January 1, 2002;
20(1):
205 - 213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sood, C. C. Stewart, P. D. Aplan, H. Murai, P. Ward, M. Barcos, and M. R. Baer
Neutropenia Associated With T-Cell Large Granular Lymphocyte Leukemia: Long-Term Response to Cyclosporine Therapy Despite Persistence of Abnormal Cells
Blood,
May 1, 1998;
91(9):
3372 - 3378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K Morris, J. M Kolesar, and J. G Kuhn
Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine
Journal of Oncology Pharmacy Practice,
June 1, 1997;
3(2):
94 - 109.
[PDF]
|
|
|
|
|
|
|
J. M. Zaucha, K. Lewandowski, A. Hellmann, H. Pawlik, A. Siedlewicz;, T. M. Kuzel, and M. S. Tallman
2-Chlorodeoxyadenosine Treatment in the Sezary Syndrome
Blood,
February 15, 1997;
89(4):
1462 - 1464.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Fidias, B. A. Chabner, and M. L. Grossbard
Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders
Oncologist,
June 1, 1996;
1(3):
125 - 139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
